{
    "nctId": "NCT03013881",
    "briefTitle": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers",
    "officialTitle": "Open-label, Two-part, Dose-escalation and Comparative Pharmacokinetics Study of UB-921 in Healthy Male Volunteers",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasm",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 18,
    "primaryOutcomeMeasure": "Adverse event incidence",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Total body weight \u226750 kg (110 lbs)\n* No clinically relevant abnormalities\n* To agree on using birth control barrier (eg. male condom) during the entire study period.\n* Signing the written informed consent form\n\nExclusion Criteria:\n\n* Previous exposure to chimeric, humanized or human monoclonal antibody, whether licensed or investigational\n* A history of drug abuse or heavy drinking.\n* Blood donation over 250 mL within 90 days prior to the screening\n* Not in the condition to participate in this study considered by investigator(s)",
    "sex": "MALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT"
}